Showing 971-980 of 23043 results for "".
Women In Aesthetics: Katie Cheng, Cynosure
https://modernaesthetics.com/topics/energy-based-devices/women-in-aesthetics-katie-cheng-cynosure/35145/Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.From Resistance to Response: Evolving Strategies in MDD Management
https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/Learn how to better recognize symptoms of major depressive disorder and explore novel therapeutic options for treatment.Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages
https://reachmd.com/programs/cme/early-clues-lasting-impact-detecting-and-treating-alzheimers-disease-in-its-earliest-stages/56389/Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies. Gain expert insights on recent data from CTAD 2025, including blood-based diagnostics, lifestyle iRAS Across Tumors: Who to Test When
https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
https://reachmd.com/clinical-practice/cardiology/primary-care-takeaways-from-vesalius-cv-evolocumab-efficacy-in-patients-without-significant-atherosclerosis/56623/Evolocumab reduced CV events even without atherosclerosis. Dr. Morales explores what earlier LDL-C lowering means for primary care.Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
https://reachmd.com/programs/cme/secondary-hyperparathyroidism-a-hidden-danger-in-chronic-kidney-disease/14973/How can you diagnose patients with SHPT earlier in CKD and control PTH levels early in the disease course? Our experts have what you need to know!Addressing Unmet Needs in Metastatic Uveal Melanoma
https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data b